Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer
05 September 2017 - 1:00PM
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty
pharmaceutical company developing pharmacological treatments for
addictions, today announced the appointment of David O’Toole as
Opiant’s Chief Financial Officer effective September 12, 2017. Mr.
O’Toole, who will be based at Opiant’s headquarters in Santa
Monica, has more than 30 years of experience in the accounting and
finance sectors, and for nearly half of his career, he has focused
on the life sciences industry. He most recently served as CFO at
Soleno Therapeutics, Inc., a company focused on the development and
commercialization of novel therapeutics for the treatment of rare
diseases. Mr. O’Toole managed the Soleno Therapeutics, Inc.
initial public offering in 2014 and raised over $40 million for the
company in a number of financing transactions. He will
succeed Kevin Pollack, Opiant’s outgoing Chief Financial
Officer, who will be stepping down on September 11, 2017 and will
continue to advise the company during the transition.
“I am delighted to welcome David O'Toole to the Opiant
management team,” stated Roger Crystal, M.D., Chief Executive
Officer of Opiant. “David brings a strong track record of success
helping growing biotechnology companies effectively manage their
assets. His solid financial and managerial expertise, along with
his skills and experience in building organizations, will be
instrumental as we advance our development programs which include
clinical candidates addressing Alcohol Use Disorder, Opioid Use
Disorder and Eating Disorders.”
“We thank Kevin for his dedication and key contributions to
Opiant during his many years of service,” Dr. Crystal
continued. “Leveraging his expertise and experience, Kevin
played an important role in building our company, adding to the
strength of our financial position and establishing a solid
foundation for our future. We wish him all the best in his
future endeavors.”
During the last nine years as CFO of four life sciences
companies, Mr. O’Toole has led numerous M&A and financing
transactions. He has significant experience in SEC reporting,
managing and building finance, treasury and accounting departments,
Sarbanes Oxley compliance and managing investor relations and
commercial operations. Prior to Soleno Therapeutics, Inc., Mr.
O'Toole served as CFO at Codexis, Inc. from 2012 to 2014 and
Response Genetics, Inc. from 2010 to 2012. Prior to that, from 2008
to 2009, Mr. O'Toole served as CFO at Abraxis BioScience, Inc.,
which was acquired by Celgene for $2.9 billion. Prior to his CFO
experience, Mr. O’Toole spent 24 years in public accounting,
including 16 years with the accounting firm of Deloitte &
Touche LLP (12 years as a partner), and began his career with eight
years at the accounting firm of Arthur Andersen. Mr. O'Toole holds
a Bachelor of Science degree in accounting from the University of
Arizona and is a Certified Public Accountant.
As Chief Financial Officer, Mr. O’Toole will be responsible for
all aspects of financial management for Opiant and will report to
Dr. Roger Crystal, Chief Executive Officer.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical
company developing pharmacological treatments for addictions. NIDA,
a division of the National Institutes of Health (NIH), describes
these disorders as chronic relapsing brain diseases which burden
society at both the individual and community levels. With its
innovative opioid antagonist nasal delivery technology, Opiant is
positioned to become a leader in these treatment markets. Its first
product, NARCAN® Nasal Spray, is approved for marketing in the U.S.
and Canada by the company’s partner, Adapt Pharma Operations
Limited. For more information please visit: www.opiant.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our
industry’s actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements, including those
risks and uncertainties described in our filings with the U.S.
Securities and Exchange Commission, including our most recent
reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
Therefore, current and prospective security holders are cautioned
that there also can be no assurance that the forward-looking
statements included in this press release will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such
information should not be regarded as a representation or warranty
by Opiant or any other person that the objectives and plans of
Opiant will be achieved in any specified time frame, if at all. In
some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,”
“expects,” “plans,” “intends,” “anticipates,” “believes,”
“estimates,” “predicts,” “projects,” “potential,” or “continue” or
the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. We undertake no obligation to update any of the
forward-looking statements after the date of this press release to
conform those statements to reflect the occurrence of unanticipated
events, except as required by applicable law.
CONTACT INFORMATION:
Corporate Contact:
Investor.relations@opiant.com
Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024